#United States #Miami #Lipocine #LPCN 1154 #ASCP Meeting

Lipocine's LPCN 1154 Phase 3 Data to Shine at ASCP 2026

Lipocine Inc., a biopharmaceutical enterprise listed on NASDAQ (LPCN), is set to present its Phase 3 clinical trial data concerning LPCN 1154 at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. This event will take place from May 26 to May 29, 2026, in Miami, Florida. The focus will be on the innovative oral treatment for postpartum depression (PPD).

Presentation Details

The Phase 3 trial data for LPCN 1154 will be highlighted in an oral presentation scheduled for May 26, 2026. The session, titled "Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154," will be delivered by Dr. Benjamin Bruno, the Vice President of Clinical Development at Lipocine. This particular session is part of the Pharmaceutical Pipeline presentations.

The presentation is anticipated to shed light on the results from a placebo-controlled trial that explored the effectiveness of LPCN 1154 in treating postpartum depression, a condition that affects many new mothers and often leads to significant emotional distress.

Additionally, a poster presentation will be featured on May 27, 2026, further illustrating the trial findings, which will be made available during the Poster Session 1 and is numbered W98.

The Significance of LPCN 1154

LPCN 1154 is an oral formulation of brexanolone, which is chemically identical to allopregnanolone, a hormone naturally produced in the human body. Unlike traditional selective serotonin reuptake inhibitors (SSRIs), this innovative treatment offers the promise of rapid symptom relief, potentially stabilizing the emotional state of postpartum patients within hours of administration without the need for intensive monitoring.

This innovative approach is applauded not only for its speed but also for its low profile of central nervous system depressant side effects. Significantly, LPCN 1154 has been designed to avoid risks associated with psychedelic substances, such as disassociation or hallucinations, thereby providing a safer option for new mothers.

Dr. Mahesh V. Patel, the President and CEO of Lipocine, expressed enthusiasm about presenting the Phase 3 data at a prestigious platform such as the ASCP meeting, acknowledgment of its value in addressing clinical research in psychopharmacology.

Company Background

Lipocine is at the forefront of biopharmaceutical innovation, utilizing a proprietary technology to develop drugs with favorable oral delivery options. Their portfolio includes several drug candidates aimed at treating various significant medical needs, reflecting commitment to expanding accessible treatment options.

In addition to LPCN 1154, Lipocine has several other candidates in their pipeline, including LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and LPCN 2401 aimed at obesity management, among others. Their FDA-approved treatment TLANDO specifically targets conditions related to testosterone deficiency in adult men, exemplifying their wide-ranging therapeutic approach.

As Lipocine gears up for its presentation in Miami, the anticipation surrounding LPCN 1154's innovative treatment for postpartum depression highlights a significant step forward in mental health therapies for new mothers, aiming to enhance their quality of life and mother-child connection during a crucial time.

For more information about Lipocine and its groundbreaking treatments, visit www.lipocine.com.